Texas MPN Workshop 2021 | Ruxolitinib’s place in the future treatment landscape for MPNs
Aaron Gerds
• 11 Aug 2021
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the placement of ruxolitinib in the treatment landscape for myeloproliferative neoplasms (MPNs) in the future. As the first approved JAK inhibitor for the treatment of myelofibrosis and due to its favourable efficacy and safety profile, ruxolitinib has been prevalent in the treatment field for MPNs, although according to Dr Gerds this may not be the case in the future. With further approvals, such as that of fedratinib based on data from the JAKARTA (NCT01437787) and JAKARTA2 trials (NCT01523171), the focus may shift away from ruxolitinib to accommodate newer agents. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
